Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience

BACKGROUND: Unresectable hepatocellular carcinoma (u-HCC) still accounts for the majority of newly diagnosed HCC which with poor prognosis. In the era of systemic therapy, combination therapy with programmed cell death protein-1 (PD-1) inhibitors and tyrosine kinase inhibitors (TKIs) has become main...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Laihui, Xiao, Yongqiang, Zhu, Guoqing, Huang, Aihong, Song, Shengjiang, Wang, Tao, Ge, Xian, Xie, Jin, Deng, Wei, Hu, Zhigao, Wen, Wu, Mei, Haoran, Wan, Renhua, Shan, Renfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552711/
https://www.ncbi.nlm.nih.gov/pubmed/36237309
http://dx.doi.org/10.3389/fonc.2022.1004652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552711/
https://www.ncbi.nlm.nih.gov/pubmed/36237309
http://dx.doi.org/10.3389/fonc.2022.1004652

Ejemplares similares